Literature DB >> 1401909

Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers.

J M Calle1, E H Nardin, P Clavijo, C Boudin, D Stüber, B Takacs, R S Nussenzweig, A H Cochrane.   

Abstract

The fine specificities of antibodies to the circumsporozoite (CS) protein of Plasmodium falciparum, present in the sera of volunteers immunized with irradiated P. falciparum sporozoites, were defined and compared to those of sera from persons living in a malaria-endemic area in West Africa. The specificity of these anti-CS antibodies was determined by ELISA, using recombinant proteins and synthetic peptides containing repeat and nonrepeat sequences of this CS protein. All 10 serum samples of the five sporozoite-immunized volunteers displayed very high antibody titers to the immunodominant repeat (NANP)n of the CS protein. However, only three of the serum samples of these vaccinees reacted with a single nonrepeat region and only at low titers. In contrast, a high percentage of sera from adults living in the malaria-endemic area who had been exposed to sporozoites, as well as liver and blood stages of P. falciparum, had high antibody levels, not only to the repeats but also to several nonrepeat regions of the CS protein. Furthermore, a number of sera from children living in this endemic area displayed appreciable levels of antibodies to the nonrepeat regions, in the absence of any antirepeat reactivity. Sera of Saimiri monkeys, which had undergone multiple blood-induced P. falciparum infections, consistently contained high titers of antibodies to several nonrepeat sequences of the CS protein, whereas only a few of these sera had low titers of antirepeat antibodies. Antibody binding sites, in nonrepeat regions, were mapped using synthetic polymers containing multiple copies of selected C-terminal sequences of the P. falciparum CS protein. The binding to sporozoites of antibodies to nonrepeat regions of the CS protein was determined. The basis for the differences in antibody binding sites of sera from persons immunized with irradiated sporozoites, compared to those from an endemic area, is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401909

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.

Authors:  D E Neafsey; M Juraska; T Bedford; D Benkeser; C Valim; A Griggs; M Lievens; S Abdulla; S Adjei; T Agbenyega; S T Agnandji; P Aide; S Anderson; D Ansong; J J Aponte; K P Asante; P Bejon; A J Birkett; M Bruls; K M Connolly; U D'Alessandro; C Dobaño; S Gesase; B Greenwood; J Grimsby; H Tinto; M J Hamel; I Hoffman; P Kamthunzi; S Kariuki; P G Kremsner; A Leach; B Lell; N J Lennon; J Lusingu; K Marsh; F Martinson; J T Molel; E L Moss; P Njuguna; C F Ockenhouse; B Ragama Ogutu; W Otieno; L Otieno; K Otieno; S Owusu-Agyei; D J Park; K Pellé; D Robbins; C Russ; E M Ryan; J Sacarlal; B Sogoloff; H Sorgho; M Tanner; T Theander; I Valea; S K Volkman; Q Yu; D Lapierre; B W Birren; P B Gilbert; D F Wirth
Journal:  N Engl J Med       Date:  2015-10-21       Impact factor: 91.245

2.  A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.

Authors:  A Birkett; K Lyons; A Schmidt; D Boyd; G A Oliveira; A Siddique; R Nussenzweig; J M Calvo-Calle; E Nardin
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

4.  Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

Authors:  Elizabeth H Nardin; Giane A Oliveira; J Mauricio Calvo-Calle; Kristiane Wetzel; Carolin Maier; Ashley J Birkett; Pramod Sarpotdar; Michael L Corado; George B Thornton; Annette Schmidt
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  Unexpected fold in the circumsporozoite protein target of malaria vaccines.

Authors:  Michael B Doud; Adem C Koksal; Li-Zhi Mi; Gaojie Song; Chafen Lu; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

6.  Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high-molecular-mass antigens.

Authors:  S Laal; K M Samanich; M G Sonnenberg; S Zolla-Pazner; J M Phadtare; J T Belisle
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

7.  P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections.

Authors:  David C Whitacre; Diego A Espinosa; Cory J Peters; Joyce E Jones; Amy E Tucker; Darrell L Peterson; Fidel P Zavala; David R Milich
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

8.  Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites.

Authors:  Danika L Hill; Emily M Eriksson; Amandine B Carmagnac; Danny W Wilson; Alan F Cowman; Diana S Hansen; Louis Schofield
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

9.  Acquisition of naturally occurring antibody responses to recombinant protein domains of Plasmodium falciparum erythrocyte membrane protein 1.

Authors:  Claire L Mackintosh; Zoe Christodoulou; Tabitha W Mwangi; Moses Kortok; Robert Pinches; Thomas N Williams; Kevin Marsh; Christopher I Newbold
Journal:  Malar J       Date:  2008-08-16       Impact factor: 2.979

10.  Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria.

Authors:  Danika L Hill; Emily M Eriksson; Connie S N Li Wai Suen; Chris Y Chiu; Victoria Ryg-Cornejo; Leanne J Robinson; Peter M Siba; Ivo Mueller; Diana S Hansen; Louis Schofield
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.